Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product

Abstract Introduction ABP 938 is being developed as a biosimilar to Eylea® (aflibercept reference product [RP]), an anti-vascular endothelial growth factor (VEGF) drug used in the management of retinal diseases. Previously, a comparative analytical similarity assessment demonstrated that ABP 938 and...

Full description

Bibliographic Details

Published in:	Ophthalmology and Therapy
Main Authors:	Neungseon Seo, Scott Kuhns, Dina A. Andrews, Alexander Colbert, Vincent Chow, Jennifer Liu
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2024-11-01
Subjects:	ABP 938 Aflibercept Biosimilar pharmaceuticals Eye diseases Nonclinical similarity Pharmacology
Online Access:	https://doi.org/10.1007/s40123-024-01043-5